Evidence map›Paper›PMID 42619090›Full record

ArticleJournal of the American Chemical Society2026

De Novo-Designed Bifunctional Proteins for Targeted Protein Degradation.

Bram Mylemans, Boguslawa Korona, Amanda M Acevedo-Jake, Ailsa MacRae, Thomas A Edwards, Danny T Huang, Andrew J Wilson, Laura S Itzhaki, Derek N Woolfson

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bram MylemansSchool of Chemistry, University of Bristol, Cantock's Close, BristolBS8 1TS, U.K.
Boguslawa KoronaDepartment of Pharmacology, University of Cambridge, CambridgeCB2 1PD, U.K.
Amanda M Acevedo-JakeSchool of Chemistry, University of Birmingham, EdgbastonB15 2TT, U.K.
Ailsa MacRaeSchool of Chemistry, University of Birmingham, EdgbastonB15 2TT, U.K.
Thomas A EdwardsCollege of Biomedical Sciences, Larkin University, 18301 N Miami Ave #1, Miami, Florida33169, U.S.A.
Danny T HuangCancer Research UK Scotland Institute, Garscube Estate, Switchback Road, GlasgowG61 1BD, U.K.
Andrew J WilsonSchool of Chemistry, University of Birmingham, EdgbastonB15 2TT, U.K.ORCID 0000-0001-9852-6366
Laura S ItzhakiDepartment of Pharmacology, University of Cambridge, CambridgeCB2 1PD, U.K.ORCID 0000-0001-6504-2576
Derek N WoolfsonSchool of Chemistry, University of Bristol, Cantock's Close, BristolBS8 1TS, U.K.ORCID 0000-0002-0394-3202

Funding

Biotechnology and Biological Sciences Research Council BB/V003577/1Biotechnology and Biological Sciences Research Council BB/V003577/2Biotechnology and Biological Sciences Research Council BB/V006231/1Biotechnology and Biological Sciences Research Council BB/V006703/1Biotechnology and Biological Sciences Research Council BB/V008412/1Biotechnology and Biological Sciences Research Council BB/V008412/2Biotechnology and Biological Sciences Research Council BB/Y007816/1Cancer Research UK A29252Novo Nordisk Foundation Center for Protein Design NNF25SA0105927
6 · The paper itself

Abstract

In targeted protein degradation (TPD), specific subcellular proteins are removed by routing them to the ubiquitin-proteasome, autophagy, or lysosome machinery. For instance, proteolysis-targeting chimeras (PROTACs) are synthetic heterobifunctional small molecules that simultaneously bind the target and an E3 ubiquitin ligase to drive ubiquitination and degradation by the proteasome. Despite considerable success, designing such molecules is challenging, and the number of currently addressable ubiquitin E3 ligases is limited. Here, we design a heterobifunctional de novo protein to trigger the degradation of a common cancer target, resulting in a desired phenotypic output. First, we developed a highly stable and adaptable helix-turn-helix scaffold for presenting multiple binding sites. Next, we use computational protein design to incorporate and embellish hot-spot-binding sites to target the antiapoptotic mediators BCL-xL and MCL-1. We show a 75% success rate for creating submicromolar binders against these targets. Crystal structures of the complexes confirmed the designed binding poses. Then, we designed short linear motifs (SLiMs) into the loop of the scaffold to recruit KLHL20 and the ubiquitin ligase machinery. These designs have low micromolar affinity for KLHL20 comparable to that of the natural SLiMs. Moreover, the bifunctionalized proteins degrade BCL-xL in cells, leading to apoptosis.

Indexed as

bcl-X ProteinProteolysisBinding SitesHumansModels, MolecularMyeloid Cell Leukemia Sequence 1 ProteinProteolysis Targeting ChimeraUbiquitin-Protein Ligasesbcl-X ProteinMyeloid Cell Leukemia Sequence 1 ProteinProteolysis Targeting ChimeraUbiquitin-Protein Ligases

Identifiers

PMID42619090
PMCPMC13495755

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.